Budget and personnel reductions at the Food and Drug Administration (FDA) initiated by President Donald Trump could hinder the timely development, approval, or commercialization of new pharmaceuticals, as suggested by numerous annual reports submitted by pharmaceutical firms to the Securities and Exchange Commission in late February.
“The Trump Administration has taken several executive actions that may impose considerable burdens on, or otherwise significantly delay, the FDA’s ability to carry out its routine regulatory and oversight functions,” states one filing from Xenon Pharmaceuticals, a Canadian company focused on researching treatments for epilepsy. “If these executive measures restrict the FDA’s capacity for oversight and implementation in the usual course of business, we could experience negative impacts.”
In February, Elon Musk’s so-called Department of Government Efficiency (DOGE) laid off hundreds of FDA employees, creating widespread anxiety regarding the future of grant applications, ongoing clinical trials, and drug approvals. Just over a week later, it reinstated a small number of staff members responsible for regulating the nation’s food supply and assessing medical devices.
This move did little to alleviate fears among various pharmaceutical companies, who are concerned that any interruption to the FDA’s slow-moving bureaucracy might cause the agency to come to a standstill. Before new drugs can be marketed, the FDA must conduct routine inspections and reviews—a process that can last several years. Many recent SEC reports indicate that if the FDA ceases this work, these drugs will simply be unable to reach the market.
Biopharmaceutical company Rezolute, which develops treatments for a rare form of congenital low blood sugar, argues that DOGE’s mission to “reduce expenditures” at agencies like the FDA could delay their efforts, according to an SEC report. The company expressed, “Our operations rely heavily on the FDA and its ability to promptly address our drug development activities.”
Some pharmaceutical companies have also pointed out DOGE’s influence at the National Institutes of Health (NIH), which allocates billions for drug research and development to both corporations and universities worldwide.
Clover Health, a healthcare company serving Medicare patients, noted in a recent filing that DOGE is generating “pressures and uncertainties” concerning the federal budget, including the debt ceiling, which it claims “could adversely affect the economic environment and limit expenditures on health and healthcare-related areas.”
Certain filings also raised concerns about the potential for Trump to reform existing drug regulations, which would require additional time and resources for compliance. A recent executive order issued by Trump mandates extensive deregulation across federal agencies, while new Health and Human Services Secretary Robert F. Kennedy Jr. has shown support for this initiative and proposed his own budgetary cuts.
DOGE recently froze $1.5 billion earmarked for medical research funding but later restored some of the funds. This flip-flop left companies uncertain about the government’s ultimate support for their research initiatives. iBio, a San Diego-based company pursuing antibody treatments for obesity and cardio-metabolic disorders, mentioned in a filing that it remains “unclear” how Trump’s healthcare policies will impact grant funding for research in its sector.
